Argent Biopharma Ltd (RGT) - Total Liabilities
Based on the latest financial reports, Argent Biopharma Ltd (RGT) has total liabilities worth AU$11.10 Million AUD (≈ $7.85 Million USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore RGT shareholders equity momentum to track the company's year-over-year net asset growth rate.
Argent Biopharma Ltd - Total Liabilities Trend (2006–2025)
This chart illustrates how Argent Biopharma Ltd's total liabilities have evolved over time, based on quarterly financial data. See Argent Biopharma Ltd (RGT) FCF generation index to measure how efficiently the company converts operating cash flow to free cash.
Argent Biopharma Ltd Competitors by Total Liabilities
The table below lists competitors of Argent Biopharma Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Champion Bear Resources Ltd.
V:CBA
|
Canada | CA$3.28 Million |
|
Australian Silica Quartz Group Ltd
AU:ASQ
|
Australia | AU$100.91K |
|
Lavoro Limited Class A Ordinary Shares
NASDAQ:LVRO
|
USA | $7.97 Billion |
|
Videndum Plc
LSE:VID
|
UK | GBX253.00 Million |
|
Qiiwi Games AB (publ)
ST:QIIWI
|
Sweden | Skr1.25 Million |
|
Clean & Carbon Energy S.A.
WAR:CCE
|
Poland | zł8.32 Million |
|
HiteJinro Holdings Co Ltd
KO:000145
|
Korea | ₩2.77 Trillion |
|
Enlivex Therapeutics Ltd
TA:ENLV
|
Israel | ILA3.46 Million |
Liability Composition Analysis (2006–2025)
This chart breaks down Argent Biopharma Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see RGT market cap overview.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.19 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.29 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 4.50 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Argent Biopharma Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Argent Biopharma Ltd (2006–2025)
The table below shows the annual total liabilities of Argent Biopharma Ltd from 2006 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-06-30 | AU$11.10 Million ≈ $7.85 Million |
-33.20% |
| 2024-06-30 | AU$16.61 Million ≈ $11.75 Million |
-7.79% |
| 2023-06-30 | AU$18.02 Million ≈ $12.75 Million |
+34.66% |
| 2022-06-30 | AU$13.38 Million ≈ $9.47 Million |
+28.51% |
| 2021-06-30 | AU$10.41 Million ≈ $7.37 Million |
+115.31% |
| 2020-06-30 | AU$4.83 Million ≈ $3.42 Million |
+119.90% |
| 2019-06-30 | AU$2.20 Million ≈ $1.56 Million |
-69.90% |
| 2018-06-30 | AU$7.30 Million ≈ $5.17 Million |
+45.16% |
| 2017-06-30 | AU$5.03 Million ≈ $3.56 Million |
+8.62% |
| 2016-06-30 | AU$4.63 Million ≈ $3.28 Million |
+680.07% |
| 2015-06-30 | AU$593.79K ≈ $420.14K |
+38.32% |
| 2014-06-30 | AU$429.29K ≈ $303.75K |
-43.44% |
| 2013-06-30 | AU$758.99K ≈ $537.03K |
+270.35% |
| 2012-06-30 | AU$204.94K ≈ $145.01K |
-34.31% |
| 2012-04-30 | AU$312.00K ≈ $220.76K |
+17.50% |
| 2011-06-30 | AU$265.52K ≈ $187.87K |
-98.46% |
| 2010-06-30 | AU$17.27 Million ≈ $12.22 Million |
+5.12% |
| 2009-06-30 | AU$16.43 Million ≈ $11.62 Million |
+2233.90% |
| 2008-06-30 | AU$703.90K ≈ $498.06K |
-27.97% |
| 2007-06-30 | AU$977.20K ≈ $691.43K |
-62.53% |
| 2006-06-30 | AU$2.61 Million ≈ $1.85 Million |
-- |
About Argent Biopharma Ltd
Argent BioPharma Limited, a clinical-stage biopharmaceutical company, develops nano-engineered therapeutics that reset the balance between the nervous and immune systems in Malta, Slovenia, Australia, and internationally. The company's principal product candidates include CimetrA, which is in phase III clinical trial for the treatment of acute lung injury and ARDS; CannEpil, which is in phase I c… Read more